Moderna Stock Surges 10% to Yearly High Amid FDA Vote
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Source: Fool
- FDA Vote Impact: Moderna's mRNA flu vaccine received a 9-0 vote of support from the FDA advisory panel, with a final approval expected by August 5, propelling the stock price up over 70% in a month to a yearly high of $79.76.
- Market Expectation Discrepancy: Despite the significant stock surge, the average analyst price target remains around $45, indicating a stark contrast between market sentiment and analyst forecasts regarding the company's growth potential, particularly concerning the flu vaccine's market viability.
- Diversification Strategy: At its Science Day in late June, Moderna outlined three commercial franchises, including infectious disease vaccines, personalized cancer therapies, and rare disease treatments, signaling a strategic shift to reduce reliance on COVID vaccines, although flu vaccine sales are not expected to contribute significantly in the near term.
- Strong Financial Position: As of the first quarter, Moderna reported $7.5 billion in cash and investments, providing ample funding for its pipeline development even as sales remain below pandemic peaks, thus offering the company time to validate its new product offerings in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 72.500
Low
17.00
Averages
32.47
High
63.00
Current: 72.500
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna's Flu Vaccine Gains FDA Advisory Panel Support
- FDA Advisory Vote: Moderna's mRNA flu vaccine received a 9-0 vote of support from the FDA advisory panel, with a final approval decision expected by August 5, positioning Moderna to potentially become the first mRNA-based seasonal flu vaccine approved in the U.S., significantly enhancing its market standing.
- Stock Surge: Following this news, Moderna's stock jumped approximately 10% on Thursday to $79.76, marking a fresh yearly high and reflecting over a 70% increase in the past month, indicating strong market optimism regarding its future growth potential.
- Diversification Strategy: While the flu vaccine market is limited, Moderna's entry into this space allows for diversification away from COVID vaccine reliance, and the company showcased its broad pipeline in infectious disease vaccines, personalized cancer therapies, and rare disease treatments during its Science Day in June, boosting investor confidence.
- Strong Financial Position: Moderna ended the first quarter with $7.5 billion in cash and investments, providing ample support for its pipeline even as sales remain well below pandemic peaks, thus granting the company valuable time and resources to transition in the post-COVID era.
See More
Moderna Stock Surges 10% to Yearly High Amid FDA Vote
- FDA Vote Impact: Moderna's mRNA flu vaccine received a 9-0 vote of support from the FDA advisory panel, with a final approval expected by August 5, propelling the stock price up over 70% in a month to a yearly high of $79.76.
- Market Expectation Discrepancy: Despite the significant stock surge, the average analyst price target remains around $45, indicating a stark contrast between market sentiment and analyst forecasts regarding the company's growth potential, particularly concerning the flu vaccine's market viability.
- Diversification Strategy: At its Science Day in late June, Moderna outlined three commercial franchises, including infectious disease vaccines, personalized cancer therapies, and rare disease treatments, signaling a strategic shift to reduce reliance on COVID vaccines, although flu vaccine sales are not expected to contribute significantly in the near term.
- Strong Financial Position: As of the first quarter, Moderna reported $7.5 billion in cash and investments, providing ample funding for its pipeline development even as sales remain below pandemic peaks, thus offering the company time to validate its new product offerings in the market.
See More
Investors Weigh Moderna Against Recursion in Biotech Landscape
- Moderna Financial Performance: In FY 2025, Moderna reported revenue exceeding $1.9 billion, a 40% decline from the previous year, resulting in a net loss of approximately $2.8 billion, reflecting financial pressure amid decreasing vaccine demand.
- Recursion Growth Potential: Recursion Pharmaceuticals generated approximately $74.7 million in revenue for FY 2025, marking a 27% year-over-year increase, despite a net loss of nearly $645 million, highlighting the tension between high investment in AI drug discovery and potential returns.
- Competitive Pressure Analysis: Moderna faces intense competition from large pharmaceutical companies like Pfizer and Sanofi, with regulatory policy changes potentially significantly impacting demand, while industry-wide uncertainty regarding mRNA intellectual property adds to future risks.
- Valuation Comparison: Moderna offers a lower sales multiple and a more established revenue base, whereas Recursion represents a higher-growth, earlier-stage investment with a price-to-sales ratio of 26.8, indicating market expectations for its future potential.
See More
Future Prospects of Moderna and Recursion
- Revenue and Loss Comparison: Moderna reported over $1.9 billion in revenue for FY 2025, a 40% decline year-over-year, resulting in a net loss of approximately $2.8 billion, indicating the financial pressures faced during its transformation.
- R&D Investment and Partnerships: By collaborating with companies like Merck, Moderna is expanding its pipeline into immuno-oncology and rare diseases, yet it must rely on these partnerships to drive research and commercialization amid fierce competition from giants like Pfizer.
- Recursion's Growth Potential: Recursion generated approximately $74.7 million in revenue for FY 2025, a 27% increase, but recorded a net loss of nearly $645 million, highlighting the high investment and risk profile in AI drug discovery, with future operations dependent on partnerships with firms like Roche.
- Market Outlook and Risks: While Moderna's mRNA platform has proven effective, declining demand for COVID vaccines has impacted its revenue, and Recursion faces uncertainties with its AI platform and potential cybersecurity risks, necessitating careful evaluation of both companies' long-term investment value.
See More
PANW, AAL, MRNA Stocks Surge Amid Optimism
- PANW Stock Surge: Palo Alto Networks (PANW) stock jumped over 3% to a 52-week high of $358.10, driven by Wells Fargo and BTIG raising their price targets to $420 and $380 respectively, reflecting strong confidence in product demand and likely enhancing the company's market share in cybersecurity.
- AAL Stock Rise: American Airlines Group (AAL) stock closed up 0.44%, reaching an annual high of $18.47, buoyed by falling global oil prices and robust travel demand, with Bernstein and BofA analysts raising their price targets to $23 and $19, indicating a positive outlook for the company's performance.
- MRNA Stock Climb: Moderna (MRNA) stock increased over 3%, hitting a new high of $73.91, following the announcement of a new strategy at Science Day to expand its mRNA platform to include infectious disease vaccines, cancer vaccines, and rare disease therapeutics, which is expected to drive future revenue growth.
- Market Sentiment Shift: As PANW, AAL, and MRNA stocks rise, retail investor sentiment has shifted from neutral to bullish, particularly with MRNA surging 134.93% in 2026, highlighting significant market interest in its new products and strategies.
See More
Moderna's Expanding Pipeline Sparks Investor Interest
- Product Line Expansion: Moderna's stock has surged nearly 150% over the past year, making it one of the best performers in the S&P 500, reflecting strong market confidence in its new product lines, although it remains below the pandemic peak of $484 in 2021.
- Cancer Treatment Progress: The company's efforts in cancer therapies have garnered investor attention, with mid and late-stage trials targeting melanoma and non-small cell lung cancer underway, with significant study results expected later this year that could drive new growth.
- Vaccine Development Advances: Moderna's experimental flu vaccine received a recommendation from the FDA advisory committee, with a regulatory decision expected on August 5, while its combination Covid and flu vaccine has been approved by the European Commission, enhancing the diversity of its product portfolio.
- Future Outlook: Cramer highlighted that Moderna has presented a clear roadmap to profitability for the first time, emphasizing its potential in cancer and vaccine sectors, and while it may take years to realize, the company's future outlook remains optimistic, advising investors to wait for the right buying opportunity.
See More
Moderna's Flu Vaccine Gains FDA Advisory Panel Support
- FDA Advisory Vote: Moderna's mRNA flu vaccine received a 9-0 vote of support from the FDA advisory panel, with a final approval decision expected by August 5, positioning Moderna to potentially become the first mRNA-based seasonal flu vaccine approved in the U.S., significantly enhancing its market standing.
- Stock Surge: Following this news, Moderna's stock jumped approximately 10% on Thursday to $79.76, marking a fresh yearly high and reflecting over a 70% increase in the past month, indicating strong market optimism regarding its future growth potential.
- Diversification Strategy: While the flu vaccine market is limited, Moderna's entry into this space allows for diversification away from COVID vaccine reliance, and the company showcased its broad pipeline in infectious disease vaccines, personalized cancer therapies, and rare disease treatments during its Science Day in June, boosting investor confidence.
- Strong Financial Position: Moderna ended the first quarter with $7.5 billion in cash and investments, providing ample support for its pipeline even as sales remain well below pandemic peaks, thus granting the company valuable time and resources to transition in the post-COVID era.
See More
Moderna Stock Surges 10% to Yearly High Amid FDA Vote
- FDA Vote Impact: Moderna's mRNA flu vaccine received a 9-0 vote of support from the FDA advisory panel, with a final approval expected by August 5, propelling the stock price up over 70% in a month to a yearly high of $79.76.
- Market Expectation Discrepancy: Despite the significant stock surge, the average analyst price target remains around $45, indicating a stark contrast between market sentiment and analyst forecasts regarding the company's growth potential, particularly concerning the flu vaccine's market viability.
- Diversification Strategy: At its Science Day in late June, Moderna outlined three commercial franchises, including infectious disease vaccines, personalized cancer therapies, and rare disease treatments, signaling a strategic shift to reduce reliance on COVID vaccines, although flu vaccine sales are not expected to contribute significantly in the near term.
- Strong Financial Position: As of the first quarter, Moderna reported $7.5 billion in cash and investments, providing ample funding for its pipeline development even as sales remain below pandemic peaks, thus offering the company time to validate its new product offerings in the market.
See More
Investors Weigh Moderna Against Recursion in Biotech Landscape
- Moderna Financial Performance: In FY 2025, Moderna reported revenue exceeding $1.9 billion, a 40% decline from the previous year, resulting in a net loss of approximately $2.8 billion, reflecting financial pressure amid decreasing vaccine demand.
- Recursion Growth Potential: Recursion Pharmaceuticals generated approximately $74.7 million in revenue for FY 2025, marking a 27% year-over-year increase, despite a net loss of nearly $645 million, highlighting the tension between high investment in AI drug discovery and potential returns.
- Competitive Pressure Analysis: Moderna faces intense competition from large pharmaceutical companies like Pfizer and Sanofi, with regulatory policy changes potentially significantly impacting demand, while industry-wide uncertainty regarding mRNA intellectual property adds to future risks.
- Valuation Comparison: Moderna offers a lower sales multiple and a more established revenue base, whereas Recursion represents a higher-growth, earlier-stage investment with a price-to-sales ratio of 26.8, indicating market expectations for its future potential.
See More
Future Prospects of Moderna and Recursion
- Revenue and Loss Comparison: Moderna reported over $1.9 billion in revenue for FY 2025, a 40% decline year-over-year, resulting in a net loss of approximately $2.8 billion, indicating the financial pressures faced during its transformation.
- R&D Investment and Partnerships: By collaborating with companies like Merck, Moderna is expanding its pipeline into immuno-oncology and rare diseases, yet it must rely on these partnerships to drive research and commercialization amid fierce competition from giants like Pfizer.
- Recursion's Growth Potential: Recursion generated approximately $74.7 million in revenue for FY 2025, a 27% increase, but recorded a net loss of nearly $645 million, highlighting the high investment and risk profile in AI drug discovery, with future operations dependent on partnerships with firms like Roche.
- Market Outlook and Risks: While Moderna's mRNA platform has proven effective, declining demand for COVID vaccines has impacted its revenue, and Recursion faces uncertainties with its AI platform and potential cybersecurity risks, necessitating careful evaluation of both companies' long-term investment value.
See More
PANW, AAL, MRNA Stocks Surge Amid Optimism
- PANW Stock Surge: Palo Alto Networks (PANW) stock jumped over 3% to a 52-week high of $358.10, driven by Wells Fargo and BTIG raising their price targets to $420 and $380 respectively, reflecting strong confidence in product demand and likely enhancing the company's market share in cybersecurity.
- AAL Stock Rise: American Airlines Group (AAL) stock closed up 0.44%, reaching an annual high of $18.47, buoyed by falling global oil prices and robust travel demand, with Bernstein and BofA analysts raising their price targets to $23 and $19, indicating a positive outlook for the company's performance.
- MRNA Stock Climb: Moderna (MRNA) stock increased over 3%, hitting a new high of $73.91, following the announcement of a new strategy at Science Day to expand its mRNA platform to include infectious disease vaccines, cancer vaccines, and rare disease therapeutics, which is expected to drive future revenue growth.
- Market Sentiment Shift: As PANW, AAL, and MRNA stocks rise, retail investor sentiment has shifted from neutral to bullish, particularly with MRNA surging 134.93% in 2026, highlighting significant market interest in its new products and strategies.
See More
Moderna's Expanding Pipeline Sparks Investor Interest
- Product Line Expansion: Moderna's stock has surged nearly 150% over the past year, making it one of the best performers in the S&P 500, reflecting strong market confidence in its new product lines, although it remains below the pandemic peak of $484 in 2021.
- Cancer Treatment Progress: The company's efforts in cancer therapies have garnered investor attention, with mid and late-stage trials targeting melanoma and non-small cell lung cancer underway, with significant study results expected later this year that could drive new growth.
- Vaccine Development Advances: Moderna's experimental flu vaccine received a recommendation from the FDA advisory committee, with a regulatory decision expected on August 5, while its combination Covid and flu vaccine has been approved by the European Commission, enhancing the diversity of its product portfolio.
- Future Outlook: Cramer highlighted that Moderna has presented a clear roadmap to profitability for the first time, emphasizing its potential in cancer and vaccine sectors, and while it may take years to realize, the company's future outlook remains optimistic, advising investors to wait for the right buying opportunity.
See More
